A 2015 landmark analysis of participants in the China Health and Retirement Longitudinal Study (CHARLS) found that non-traditional lipid indices provide limited but measurable additional information for predicting incident cardiovascular disease beyond the C-reactive protein-triglyceride-glucose index (CTI). The primary finding indicates that while higher CTI values are strongly associated with increased cardiovascular risk, the Castelli risk index II (CRI-II) retains a modest independent association with incident disease even after adjusting for CTI.
The research team addressed a specific gap in understanding whether non-traditional lipid parameters (nTLPs) offer predictive value that is not already captured by CTI. CTI integrates inflammatory and insulin-resistance-related information, whereas nTLPs summarize complementary features of atherogenic lipid metabolism. The study aimed to characterize whether these lipid measures provide distinct information when accounting for repeated measurements, shared components, selection biases, and predictive optimism.
From 17,708 Wave-1 respondents in CHARLS, 4,420 participants met the strict requirements for the landmark, paired-biomarker availability, covariate completeness, and follow-up duration. These participants were classified into operational CKM stages 0–3.
The primary inferential family of the analysis comprised five time-weighted dual-high versus dual-low contrasts for incident cardiovascular disease. These contrasts compared participants with high levels of both CTI and a specific lipid index against those with low levels of both. The lipid indices evaluated alongside CTI included the atherogenic index of plasma (AIP), non-HDL cholesterol, Castelli risk index I (CRI-I), Castelli risk index II (CRI-II), and the lipoprotein combine index (LCI). The analysis employed Benjamini-Hochberg false-discovery-rate control to account for multiple testing. Additionally, the researchers compared alternative exposure summaries, decomposed CTI into its TyG and high-sensitivity C-reactive protein (hs-CRP) components, and examined competing risks, interval ascertainment, selection, censoring, missing data, and calibration.
The hazard ratio per standard deviation was 1.14 (95% CI 1.07–1.23) for the 2011 value, 1.14 (95% CI 1.06–1.23) for the 2015 value, 1.17 (95% CI 1.09–1.25) for the two-visit mean, and 1.19 (95% CI 1.11–1.27) for the time-weighted summary. In contrast, the change score over time was not clearly associated with cardiovascular disease. Across the five primary dual-high contrasts, adjusted hazard ratios ranged from 1.45 to 1.64, and these associations remained significant after false-discovery-rate correction. Competing-risk and post-landmark censoring-weighted estimates were similar to the primary models, suggesting robustness to different analytical approaches.
When assessing the incremental contribution of each non-traditional lipid index beyond CTI in mutually adjusted models, CRI-II retained the clearest independent association. The hazard ratio per standard deviation for CRI-II was 1.13 (95% CI 1.05–1.21), with a false-discovery-rate adjusted P-value of 0.003. This suggests that CRI-II captures aspects of lipid risk that are not fully explained by the inflammatory and insulin-resistance components of CTI. However, formal interaction effects were generally limited, indicating that the elevated hazards in dual-high groups likely reflect the concurrent burden of metabolic-inflammatory and lipid factors rather than a statistical interaction between the two markers.
The study also evaluated the predictive performance of these indices against a clinical benchmark. CTI and its directly estimated components produced very similar optimism-corrected discrimination, with a C-index of approximately 0.635 to 0.636. This indicates that while the indices are associated with risk, their ability to distinguish between individuals who will and will not develop cardiovascular disease is modest. The two-visit time-weighted metric behaved similarly to the two-visit mean, and internally validated prediction gains from adding the lipid indices to the clinical benchmark were small.
The authors conclude that higher CTI and more atherogenic lipid profiles identify a higher-risk phenotype in this selected 2015 landmark cohort. The findings support a component-oriented interpretation of CTI and non-traditional lipid index phenotypes, suggesting that these markers reflect different but related aspects of cardiovascular risk. The study provides a basis for further evaluation in cohorts with adjudicated outcomes and external validation. Limitations include the operational definition of CKM stages, the reliance on reported rather than adjudicated cardiovascular events, and the specific demographic and temporal context of the CHARLS cohort.
Subject of Research: Incremental predictive value of non-traditional lipid indices beyond CTI for incident cardiovascular disease in a Chinese cohort with CKM stages 0-3.
Article Title: Non-traditional lipid indices beyond the C-reactive protein-triglyceride glucose index and incident cardiovascular disease: a 2015 landmark analysis in China Health and Retirement Longitudinal Study (CHARLS) participants with operationally defined cardiovascular-kidney-metabolic syndrome (CKM) stages 0–3
Article References: Lu, A.-M., Xu, Q., Zhang, Y.-X., Qiu, Z.-K., Bai, S.-K., & Han, H.-J. (2026). Non-traditional lipid indices beyond the C-reactive protein-triglyceride glucose index and incident cardiovascular disease: a 2015 landmark analysis in China Health and Retirement Longitudinal Study (CHARLS) participants with operationally defined cardiovascular-kidney-metabolic syndrome (CKM) stages 0–3. Cardiovascular Diabetology. https://doi.org/10.1186/s12933-026-03390-y
Image Credits: AI Generated
DOI: 10.1186/s12933-026-03390-y
Keywords: Cardiovascular Disease, Lipid Indices, CTI, CRI-II, CHARLS, CKM Syndrome, Landmark Analysis, Risk Prediction, Metabolic Health, Epidemiology, Non-traditional, lipid
News Source: Ophelia Keating. (November 10, 2026). Lipid Indices Show Modest Added Value Beyond CTI for CVD Risk. Scienmag.



